New combo aims to wipe out stomach cancer before surgery
NCT ID NCT04661150
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times
Summary
This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will receive the combo or standard treatment. The main goal is to see if the cancer completely disappears in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
First Hospital of China Medical University
Shenyang, 110001, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Liaoning Provincial Cancer Hospital
Shengyang, 110042, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, 510515, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjing, 300060, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.